α-Syn-PMCA in cerebrospinal fluid has diagnostic potential in Parkinson’s disease

Parkinson’s disease (PD) is the second most common neurodegenerative disease, with the prevalence of approximately 1% at age >60 years and 4% at age >80 years worldwide (1,2). The major pathological findings in PD are the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and the presence of intraneuronal inclusions, Lewy bodies (3). Clinically, PD is characterized by motor symptoms, including bradykinesia, rigidity, resting tremor, and postural instability (4). PD is also associated with a high incidence of various non-motor symptoms, such as hyposmia, constipation, sleep problems, dysautonomia and psychological symptoms (4,5).